Neurology Central

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma


Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL.

To view restricted content, please:

Leave A Comment